Literature DB >> 28179738

Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma.

Alexandra P Punke, J Aubrey Waddell, Dominic A Solimando.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.

Entities:  

Year:  2017        PMID： 28179738      PMCID： PMC5278911          DOI： 10.1310/hpj5201-27

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  16 in total

1.  Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

Authors:  Paul G Richardson; Hannah Briemberg; Sundar Jagannath; Patrick Y Wen; Bart Barlogie; James Berenson; Seema Singhal; David S Siegel; David Irwin; Michael Schuster; Gordan Srkalovic; Raymond Alexanian; S Vincent Rajkumar; Steven Limentani; Melissa Alsina; Robert Z Orlowski; Kevin Najarian; Dixie Esseltine; Kenneth C Anderson; Anthony A Amato
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

2.  Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.

Authors:  Murielle Roussel; Valérie Lauwers-Cances; Nelly Robillard; Cyrille Hulin; Xavier Leleu; Lotfi Benboubker; Gérald Marit; Philippe Moreau; Brigitte Pegourie; Denis Caillot; Christophe Fruchart; Anne-Marie Stoppa; Catherine Gentil; Soraya Wuilleme; Anne Huynh; Benjamin Hebraud; Jill Corre; Marie-Lorraine Chretien; Thierry Facon; Hervé Avet-Loiseau; Michel Attal
Journal:  J Clin Oncol       Date:  2014-07-14       Impact factor: 44.544

3.  Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

Authors:  Shaji Kumar; Ian Flinn; Paul G Richardson; Parameswaran Hari; Natalie Callander; Stephen J Noga; A Keith Stewart; Francesco Turturro; Robert Rifkin; Jeffrey Wolf; Jose Estevam; George Mulligan; Hongliang Shi; Iain J Webb; S Vincent Rajkumar
Journal:  Blood       Date:  2012-03-15       Impact factor: 22.113

Review 4.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

5.  Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

Authors:  Patricia M LoRusso; Karthik Venkatakrishnan; Ramesh K Ramanathan; John Sarantopoulos; Daniel Mulkerin; Stephen I Shibata; Anne Hamilton; Afshin Dowlati; Sridhar Mani; Michelle A Rudek; Chris H Takimoto; Rachel Neuwirth; Dixie-Lee Esseltine; Percy Ivy
Journal:  Clin Cancer Res       Date:  2012-03-06       Impact factor: 12.531

6.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Authors:  Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau
Journal:  Lancet Oncol       Date:  2011-04-18       Impact factor: 41.316

7.  Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.

Authors:  Victor H Jimenez-Zepeda; Donna E Reece; Suzanne Trudel; Christine Chen; Rodger Tiedemann; Vishal Kukreti
Journal:  Leuk Lymphoma       Date:  2013-01-02

8.  A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Authors:  Paul G Richardson; Wanling Xie; Sundar Jagannath; Andrzej Jakubowiak; Sagar Lonial; Noopur S Raje; Melissa Alsina; Irene M Ghobrial; Robert L Schlossman; Nikhil C Munshi; Amitabha Mazumder; David H Vesole; Jonathan L Kaufman; Kathleen Colson; Mary McKenney; Laura E Lunde; John Feather; Michelle E Maglio; Diane Warren; Dixil Francis; Teru Hideshima; Robert Knight; Dixie-Lee Esseltine; Constantine S Mitsiades; Edie Weller; Kenneth C Anderson
Journal:  Blood       Date:  2014-01-15       Impact factor: 22.113

9.  Analysis of decision making at a multidisciplinary head and neck tumor board incorporating evidence-based National Cancer Comprehensive Network (NCCN) guidelines.

Authors:  Bhartesh A Shah; Muhammad M Qureshi; Scharukh Jalisi; Gregory Grillone; Andrew Salama; Timothy Cooley; Ken Zaner; Osamu Sakai; Minh Tam Truong
Journal:  Pract Radiat Oncol       Date:  2015-11-14

Review 10.  Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.

Authors:  A Palumbo; S V Rajkumar; M A Dimopoulos; P G Richardson; J San Miguel; B Barlogie; J Harousseau; J A Zonder; M Cavo; M Zangari; M Attal; A Belch; S Knop; D Joshua; O Sezer; H Ludwig; D Vesole; J Bladé; R Kyle; J Westin; D Weber; S Bringhen; R Niesvizky; A Waage; M von Lilienfeld-Toal; S Lonial; G J Morgan; R Z Orlowski; K Shimizu; K C Anderson; M Boccadoro; B G Durie; P Sonneveld; M A Hussein
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528
View more
  1 in total

1.  Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles.

Authors:  Nicolas Borisov; Anna Sergeeva; Maria Suntsova; Mikhail Raevskiy; Nurshat Gaifullin; Larisa Mendeleeva; Alexander Gudkov; Maria Nareiko; Andrew Garazha; Victor Tkachev; Xinmin Li; Maxim Sorokin; Vadim Surin; Anton Buzdin
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.